INTRODUCTION
In recent years, there has been new interest in the role of bile acids in diverse diseases including obesity, glycemic control and Clostridium difficile infection, besides bile acid diarrhea (BAD), although the latter still remains the predominant condition associated with altered bile acid balance.
BAD is a significant cause of diarrhea. There are three types of BAD: type 1, bile acid malabsorption, is secondary to ileal resection or active ileal disease; type 2 is associated with increased bile acid production; and type 3 is associated with other gastrointestinal conditions that result in malabsorption of bile acids, such as postcholecystectomy, celiac disease, chronic pancreatitis and microscopic colitis.
The first section reviews recent advances in the epidemiology, pathophysiology, diagnosis and short-term and long-term outcomes of treatment of BAD, with particular focus on type 2 BAD. In order to place recent advances in context, we include the use of 75 selenium homotaurocholic acid test ( 75 SeHCAT), 7 a-hydroxy-cholesten-3-one (C4), serum fibroblast growth factor and the treatment of BAD with bile acid sequestrants.
EMERGING EPIDEMIC: EPIDEMIOLOGY OF TYPE 2 BILE ACID DIARRHEA
Type 2 BAD is estimated to occur in 28.1% of patients with irritable bowel syndrome-diarrhea (IBS-D) in secondary and tertiary centers in the UK and Sweden [1] . This estimate was based on a pooled analysis using diverse (Manning, Kruis, Rome I, II or III) criteria for IBS-D and a positive 75 SeHCAT study of less than 10% retention. The estimate is similar to an average 25% of type 2 BAD in functional diarrhea or IBS-D, based on 75 SeH-CAT less than 10%, or increased fasting serum FGF-19, C4 or 48-h fecal bile acid excretion from studies published from diverse centers [2] . 75 SeHCAT was the most widely used test for the diagnosis of BAD.
There is also an increased appreciation of BAD in microscopic colitis [3] .
ENTEROHEPATIC CIRCULATION OF BILE ACIDS
Bile acids are produced from cholesterol in the liver. The rate-limiting enzyme in bile acid synthesis is 7a-hydroxylase (cytochrome P4507A1 CYP7A1); C4, an intermediary in the pathway of cholesterol synthesis, is measurable in serum. The primary bile acids produced in the liver are cholic acid and chenodeoxycholic acid (CDCA), which are conjugated with taurine and glycine and are excreted into bile and stored in the gallbladder (Fig. 1 ) [4] . In response to feeding, primary bile acids are released into the small bowel and aid in the digestion of fat by formation of micelles. Most of the bile acids (95%) are absorbed in the conjugated form by active transporters [apical sodium bile acid transporter (ASBT) or ileal bile acid transporter (IBAT)] in the terminal ileum and transported to the liver via the portal circulation to be recycled and reused. Cholic acid and CDCA absorbed by the ileal enterocytes bind to farnesoid X-receptor (FXR), which stimulates synthesis of FGF-19. FGF-19 is transported via the portal circulation and enters the hepatocyte through fibroblast growth factor-receptor 4 with interaction with a surface protein, klotho b, and inhibits bile acid synthesis in the hepatocyte through actions on CYP7A1.
In the colon, cholic acid and CDCA are deconjugated and dehydroxylated to secondary bile acids, predominantly deoxycholic acid (DCA) and lithocholic acid. The colon reabsorbs passively by diffusion about 75% of the bile acids passing the ileocecal
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RECENT INSIGHTS ON BILE ACID DIARRHEA AND ENTEROHEPATIC CIRCULATION

What causes primary bile acid diarrhea?
Type 2 (or primary) BAD is associated with decreased circulating levels of FGF-19, an indirect measure of decreased ileal FGF-19 production, and with lack of feedback inhibition of hepatic synthesis of bile acids leading to high colonic concentrations and increase in fecal bile acid loss [8] . Mutations of the SLC10A2 gene (for ASBT or IBAT) are rare, and normal ileal uptake of bile acids has been demonstrated, excluding membrane transport, as the cause of decreased FGF-19 production. However, a recent study showed decreased baseline expression of FGF-19 and ASBT measured by mRNA in ileal biopsies obtained from fasting patients with BAD (demonstrated by low 75 SeHCAT values) [9 && ]. These differences in expression were not the result of differences in genetic polymorphisms in the genes encoding the proteins and transporters on the enterohepatic circulation between patients with primary BAD (defined by 75 SeHCAT < 15%) and those with idiopathic diarrhea [9 && ]. On the contrary, variants in genes involved in feedback regulation of bile acid synthesis [Klotho b (KLB), P ¼ 0.06 and FGF-R4, P ¼ 0.09] were potentially associated with a subgroup with elevated serum C4 [10] . Genetic polymorphisms in KLB, FGF-R4 and GPBAR1 (TGR5) are all associated with accelerated colonic transit that is attributed to increased hepatocyte synthesis or responsiveness of the bile acid receptor (summarized in Fig. 2 ) [11] .
What is the bile acid target receptor?
TGR5 is a G protein coupled receptor located in the epithelial surface of gallbladder and intestinal cells. It is also located in the basolateral surface of smooth muscle, neural and immune cells. Bile acids activate TGR5 in enteroendocrine cells to produce glucagonlike peptide 1 (GLP-1), primarily via targeting the receptors on the basolateral surface [12 & ]. GLP-1 improves glucose homeostasis by inhibiting gastric motility, and by stimulating insulin secretion and inhibiting glucagon secretion by the pancreas [4] . TGR5 is an important receptor for mediating effects of bile acids on motility, directly by action of TGR5 14] . In addition, total and primary bile acids were significantly associated with colonic transit at 48 h in these patients with normal C4 levels [14] . These data suggest that, even in the absence of overt BAD, there may be effects of bile acids that contribute to the diarrhea.
What about interaction of bile acids and microbiome in irritable bowel syndrome?
In-vitro deconjugation of glycine-conjugated ursodeoxycholic acid to ursodeoxycholic acid in feces of patients with IBS was decreased compared with feces from healthy volunteers. There were no differences in effects between IBS subtypes (IBS-C vs. IBS-D). These data suggest that alterations in microbiome may play a role in the differences in effects of bile acids in IBS subgroups [13 & ]. In this same study, the microbiome of IBS-D had higher relative counts of Escherichia coli in IBS-D and Bacteroides and Bifidobacterium in IBS-C. None of the patients had type 2 BAD (according to serum C4 levels). The reason for the increase in fecal primary bile acid proportions may be alteration in microbiota in IBS or failure of dehydroxylation due to rapid colonic transit in patients with IBS-D.
A novel role for a nonsecretory secondary bile acid, ursodeoxycholic acid, in Clostridium difficile sporulation, infection and pouchitis
The restoration of secondary bile acid metabolism may be the key mechanism for fecal microbiota transplantation (FMT) in treating recurrent C. difficile infection. Thus, bile acids at concentrations found in patients after FMT did not induce germination and inhibited vegetative growth of C. difficile strains [15 && ]. Moreover, administration of UDCA eradicated C. difficile infection in a patient with recurrent pouchitis [16 & ]. Complete microbial engraftment following FMT is not required to recover from recurrent C. difficile infection, and secondary bile acid metabolism could potentially provide resistance to infection [17] . Individuals cured by autologous FMT typically harbored greater relative abundance of members of the Clostridium XIVa clade or Holdemania in the family Erysipelotrichaceae, as well as Parasutterella pre-FMT. The authors proposed that individuals who recovered following autologous FMT may have done so, at least in part, because of the presence of taxa active in secondary bile acid biosynthesis [17] .
DIAGNOSIS OF BILE ACID DIARRHEA
The most commonly used test for the diagnosis of BAD since 1983 is the 75 SeHCAT test. The 75 SeHCAT utilizes a taurine conjugate of 23-selena-25-homocholic acid (SeHCAT) which is given to the patient orally. 75 SeHCAT is reabsorbed and recirculated by the same process as natural bile acids [18] . A baseline scan by a g counter detects 75 SeHCAT activity, and a repeat scan is done in 7 days to determine the amount (percentage) of 75 SeHCAT retained. 75 SeH-CAT retention less than 10% suggests moderate BAD and less than 5% suggests severe BAD. These cutoffs have been corroborated with response to bile acid sequestrants of 80 and 96%, respectively, compared with 70% in patients with 75 SeHCAT retention less than 15% [19] .
A 48-h stool collection for total fecal bile acids is done during the last 2 days of ingestion of a high-fat diet and is the gold standard for measurement of bile acid excretion with a value of more than 2337 mM/48 h as the cutoff for abnormal [10] . The test is available in a few laboratories; it is used clinically for diagnosis of BAD and is available as a reference laboratory test for centers in the United States.
A recent advance in the diagnosis of BAD is the measurement of fasting FGF-19, based on a commercially available ELISA. A fasting level of less than 145 pg/ml has 61 and 82% positive and negative predictive value, respectively, for BAD using 75 SeH-CAT retention of less than 10% as a gold standard [20] . A recent study confirmed low FGF-19 in patients with BAD compared with diarrhea controls (62-70 pg/ml and 103-116 pg/ml, respectively).
The recent values are lower than prior reports, and robust values to define what is abnormal are required to establish FGF-19 as a clinical diagnostic test. In addition, postprandial levels may also prove useful, but require validation [21 & ]. The picture is further complicated by past work that demonstrated a triphasic response of FGF-19 postmeals with an initial decrease, followed by an increase and subsequent decrease.
Another diagnostic test for BAD is increased serum C4, a bile acid precursor. In patients with all three types of BAD, fasting C4 more than 35 ng/ ml had sensitivity and specificity of 87 and 86% when compared with 75 SeHCAT retention of less than 10%. This translates to a high negative likelihood ratio of 94% and positive likelihood ratio of 71%. The same ratios increase to 98 and 74%, respectively, when response to bile acid sequestrant is used as the gold standard [22] . This has been further validated in other studies. The timing of measurements is important; serum C4 has two peaks at noon and at 9 : 00 p.m. [23] . There is great promise in the development of serum C4 test for use in clinical practice in the United States through reference laboratories. Fasting serum C4 more than 52.5 ng/ml defines abnormal values in our laboratory [24] .
TREATMENTS FOR BILE ACID DIARRHEA
Bile acid sequestrants
Bile acid sequestrants are approved for the treatment of hyperlipidemia. They bind bile acids and decrease their potential to cause diarrhea. They are the treatment of choice for BAD. There are three currently available bile acid sequestrants: cholestyramine (powder form), colestipol and colesevelam (both available in tablet form).
There has been only one randomized trial of cholestyramine efficacy in BAD, defined by a mean of three stools per day with less than one watery stool per day. The trial showed response rates of 40 and 53.8% in patients with 75 SeHCAT retention of less than 10 or 20%, respectively. In comparison, the placebo hydroxypropyl cellulose group showed response rates of 25 and 38.5%, respectively (no statistical difference between the two treatments) [25 && ]. However, there was a statistically significant difference in the decreased number of watery stools with cholestyramine compared with hydroxypropyl cellulose, which also binds bile salts in the colon without affecting hepatic bile acid synthesis [26] . Eleven percent of the cholestyramine group had to discontinue treatment because of side-effects and unpalatability [27] .
Colestipol has been assessed in an open-label trial in patients with 75 SeHCAT retention of less than 20% in whom it reduced stool frequency and IBS severity score using the IBS Severity Scoring System [28] .
Colesevelam, 1875 mg daily, was tested in an open-label study in patients with BAD and resulted in a decrease in average stool consistency and increase in stool excretion of fecal bile acids, which was reflected in an increase in C4 [29] .
Patients will likely need long-term therapy with bile acid sequestrants for symptom relief. In a recent long-term follow-up study of patients with a median time from diagnosis of 6.8 years, 38% were still on bile acid sequestrants with adequate relief of their symptoms, whereas 24% had discontinued therapy, with the most common reason being tolerability [30 && ].
Farnesoid X-receptor agonist 
Low-fat diet
A low-fat diet improves several gastrointestinal symptoms including urgency to open bowels, abdominal bloating, bowel frequency, lack of control and flatulence when used alone in mild BAD or in those with 75 SeHCAT retention of 10-15%, or when used in combination with colesevelam in patients with severe BAD or in those with 75 SeHCAT retention less than 5% [32] .
ROLE OF BILE ACIDS IN EFFECTS OF ROUX-EN-Y BARIATRIC SURGERY
There is an increase in the total bile acid pool and in alteration of composition of bile acids after Roux-en-Y-gastric bypass and vertical sleeve gastrectomy (VSG). An increase in bile acids has been linked to the improved glucose homeostasis and sustained weight loss post bariatric surgery. The increase in bile acids is associated with increase in circulating GLP-1, caused by stimulation of GLP-1 secretion from intestinal enteroendocrine L cells Bile acid disease: the emerging epidemic Oduyebo and Camilleri via the GPBAR1/TGR5 receptor. FXR has also been shown to be a target that mediates effects of VSG [33] .
CONCLUSION
BAD is a significant and treatable cause of diarrhea in patients with chronic idiopathic diarrhea and should be evaluated as the cause in these patients. Studies on the mechanisms and diagnosis are progressing rapidly, and the renewed interest in the role of bile acids is leading to novel management of human diseases including obesity, glycemic control and recurrent C. difficile infection.
